CASE REPORT
Treatment-related mortality in the course of acute lymphoblastic leukemia – case report
 
More details
Hide details
1
Student Scientific Society / Department of Paediatric Haematology, Oncology and Transplantology, Medical University, Lublin, Poland
 
These authors had equal contribution to this work
 
 
Corresponding author
Karol Bigosiński   

Student Scientific Society / Department of Paediatric Haematology, Oncology and Transplantology, Medical University, 20-093 Lublin, Gębali 6, Poland
 
 
 
KEYWORDS
TOPICS
ABSTRACT
The treatment of acute lymphoblastic leukemia (ALL) in children has become increasingly effective over the years. Currently, the cure rate is about 90%. This has become possible due to the use of combinations of appropriate chemotherapeutics in very high, often maximum doses. This is associated with the occurrence of so-called treatment-related mortality (TRM), the main cause of which is infections. The case report is presented of a 12-year-old patient who contracted a respiratory syncytial virus (RSV) infection during the consolidation phase of ALL treatment. The course of the infection was so severe that despite intensive antimicrobial treatment and a stay in an intensive care unit (ICU) the patient died. This indicates the absolute necessity of constant monitoring of a patient’s condition and consideration of early inclusion of antimicrobial prophylaxis, especially in patients at risk.
 
REFERENCES (16)
1.
Bhojwani D, Yang JJ, Pui CH. Biology of childhood acute lymphoblastic leukemia. Pediatr Clin North Am. 2015;62(1):47–60. doi:10.1016/j. pcl.2014.09.004.
 
2.
Masetti R, Muratore E, Leardini D, et al. Gut microbiome in pediatric acute leukemia: from predisposition to cure. Blood Adv. 2021;5(22):4619–4629. doi:10.1182/bloodadvances.2021005129.
 
3.
Coccaro N, Anelli L, Zagaria A, et al. Next-Generation Sequencing in Acute Lymphoblastic Leukemia. Int J Mol Sci. 2019;20(12):2929. doi:10.3390/ijms20122929.
 
4.
O’Connor D, Bate J, et al. Infection-related mortality in children with acute lymphoblastic leukemia: an analysis of infectious deaths on UKALL2003. Blood. 2014;124(7):1056–61. doi:10.1182/blood-2014-03-560847.
 
5.
Malczewska M, Kośmider K, Bednarz K, et al. Recent Advances in Treatment Options for Childhood Acute Lymphoblastic Leukemia. Cancers (Basel). 2022;14(8):2021. doi:10.3390/cancers14082021.
 
6.
Inaba H, Pei D, Wolf J, et al. Infection-related complications during treatment for childhood acute lymphoblastic leukemia. Ann Oncol. 2017;28(2):386–392. doi:10.1093/annonc/mdw557.
 
7.
Gupta S, Antillon FA, Bonilla M, et al. Treatment-related mortality in children with acute lymphoblastic leukemia in Central America. Cancer. 2011;117(20):4788–95. doi:10.1002/cncr.26107.
 
8.
Ullah A, Ghafoor T, Ahmad I, et al. Predictors of Mortality in Pediatric Acute Lymphoblastic Leukemia: Analysis of 1004 Cases. Adv Basic Med Sci. 2023;7(1). doi:10.35845/abms.2023.1.273.
 
9.
Oskarsson T, Söderhäll S, Arvidson J, et al. Treatment-related mortality in relapsed childhood acute lymphoblastic leukemia. Pediatr Blood Cancer. 2018;65(4). doi:10.1002/pbc.26909.
 
10.
Lund B, Åsberg A, Heyman M, et al. Risk factors for treatment related mortality in childhood acute lymphoblastic leukaemia. Pediatr Blood Cancer. 2011;56(4):551–9. doi:10.1002/pbc.22719.
 
11.
Rahat-Ul-Ain, Faizan M, Shamim W. Treatment-related mortality in children with acute lymphoblastic leukaemia in a low-middle income country. J Pak Med Assoc. 2021;71(10):2373–2377. doi:10.47391/JPMA.796.
 
12.
Kowalczyk JR, Zawitkowska J, Lejman M, et al. Long-term treatment results of Polish pediatric and adolescent patients enrolled in the ALL IC-BFM 2002 trial. Am J Hematol. 2019;94(11):E307-E310. doi:10.1002/ ajh.25619.
 
13.
Zawitkowska J, Drabko K, Szmydki-Baran A, et al. Infectious profile in children with ALL during chemotherapy: A report of study group for infections. J Infect Chemother. 2019;25(10):774–779. doi:10.1016/j. jiac.2019.04.005.
 
14.
Loeffen EAH, Knops RRG, Boerhof J, et al. Treatment-related mortality in children with cancer: Prevalence and risk factors. Eur J Cancer. 2019;121:113–122. doi:10.1016/j.ejca.2019.08.008.
 
15.
Styczyński J. Infectious complications in children and adults with hematological malignancies. Acta Haematologica Polonica. 2019;50(3):167–173. doi:10.2478/ahp-2019-0027.
 
16.
Zawitkowska J, Drabko K, Czyżewski K, et al. Viral Infection Profile in Children Treated for Acute Lymphoblastic Leukemia-Results of Nationwide Study. Pathogens. 2022;11(10):1091. doi:10.3390/ pathogens11101091.
 
eISSN:1898-7516
ISSN:1898-2395